Antimicrobial resistance (AMR) in VDEC

AI Summary

The Vaccine Development and Evaluation Centre (VDEC), a component of the UK Health Security Agency (UKHSA), is dedicated to the discovery and evaluation of vaccines and therapeutics to combat antimicrobial resistance (AMR). While the provided document does not detail specific inspection dates or regulatory violations—as it serves as an informational overview of VDEC’s capabilities—it identifies the global threat of drug-resistant pathogens, such as tuberculosis and multidrug-resistant fungi, as the primary challenge being addressed. VDEC operates within the regulatory framework of the Department of Health and Social Care (DHSC) National Action Plan for AMR and adheres to commitments established by the United Nations and the World Health Organization. The center also participates in the Pathways to Antimicrobial Clinical Efficacy (PACE) programme to accelerate treatment delivery. VDEC utilizes advanced methods including bacteriophages, immune modulators, and biofilm disruptors to prevent resistance and improve patient outcomes. To further these goals, VDEC requires active engagement from industry, academia, and government partners, encouraging these entities to contact the UKHSA to leverage the center's unique research and diagnostic capabilities for pandemic preparedness.